132112-35-7
132112-35-7 結(jié)構(gòu)式
基本信息
(S)-1-丙基-2',6'-二甲基苯胺甲酰基哌啶單鹽酸鹽一水合物
(s)-羅哌卡因鹽酸鹽
(-)-S)-N-(2,6-二甲基苯基)-1-正丙基哌啶-2-甲酰胺鹽酸鹽
鹽酸羅哌卡因
ROPIVACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
ROPIVCACAINE HYDROCHLORIDE
S-ROPIVACAINE HCL
(S)-ROPIVACAINE HYDROCHLORIDE
(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine monohydrochloride monohydrate
(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine,monohydrochloride,monohydrate
(S)-Ropivaxaine hydrochloride
(S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
Ropivacaine hydrochloride
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide Hydrochloride Hydrate
LEA-103
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
外科手術(shù)麻醉
-----硬膜外麻醉，包括剖宮產(chǎn)術(shù)
-----蛛網(wǎng)膜下腔麻醉
-----區(qū)域阻滯
急性疼痛控制
-----持續(xù)硬膜外輸注或間歇性單次用藥，如術(shù)后或陰道分娩鎮(zhèn)痛
-----區(qū)域阻滯
鹽酸羅哌卡因的一般副作用有低血壓、惡心、心動(dòng)過緩、焦慮、感覺減退。
IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Ropivacaine HCl是一種局部麻醉劑。Ropivacaine HCl通過可逆抑制神經(jīng)纖維中鈉離子流引起神經(jīng)阻滯。Ropivacaine HCl的pKa是~8.2。Ropivacaine HCl在高血漿濃度下具有誘導(dǎo)心血管毒性和CNS毒性的可能性。
Epidural administration of Ropivacaine hydrochloride monohydrate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine hydrochloride monohydrate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
| Animal Model: | Adult Sprague-Dawley rats (300–400g) |
| Dosage: | 1 μM |
| Administration: | Infusion (added to the perfusate reservoir) |
| Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |